您当前的位置:
Ginkgolic Acid C15:1 (Synonyms: 银杏酸; Ginkgolic acid (15:1); Ginkgolic acid I; Romanicardic acid)
目录号: PC10212 纯度: ≥98%
CAS No. :22910-60-7
商品编号 规格 价格 会员价 是否有货 数量
PC10212-1mg 1mg ¥607.60 请登录
PC10212-5mg 5mg ¥1470.00 请登录
PC10212-10mg 10mg ¥2450.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Ginkgolic Acid C15:1
中文别名
银杏酸;6-[(8Z)-十五烯基]水杨酸;白果酸;银杏酸GA15:1;白果酸(银杏酸C15:1);银杏酚酸 I(P);银杏酚酸(15:1);银杏酚酸I;银杏酸 C15:1;银杏酸 C15-1;银杏酸(C15:1);银杏酸(C15:1) 白果酸;银杏酸(C17:1);银杏酸.银杏酸C15:1;银杏酸15:1;银杏酸GA17:2;白果新酸;银杏黄酮;6-[(8Z)-十五烯基]-水杨酸;银杏酸C15:1
英文名称
Ginkgolic Acid C15:1
英文别名
(Z)-2-Hydroxy-6-(pentadec-8-en-1-yl)benzoic acid;6-[(8Z)-Pentadecenyl]-salicylic acid;Ginkgolic Acid;Ginkgolic Acid (C15:1);2-hydroxy-6-[(Z)-pentadec-8-enyl]benzoic acid;Ginkgolic acid C15:1;Ginkgolic acid I;GINKGOLIC ACID I(P) PrintBack;(Z)-6-[8-pentadecenyl]salicylic acid;15:1 anacardic acid;2-hydroxy-6-(8-pentadecenyl) salicylic acid;2-Hydroxy-6-(pentadec-8-en-1-yl)benzoic acid;2-hydroxy-6-pentadec-8(Z)-enylbenzoic acid;6-(8-pentadecenyl)salicylic acid;6-[(8Z)-Pentadecenyl]-salicylic acid,Ginkgolic acid I;6-<8(Z)-pentadecenyl>salicylic acid;Anacardic acid monoene;Gingkolic Acid;Ginkgo;Ginkgoic acid;Ginkgolic acid (15:1);Ginkgolic acid 15:1;Ginkgolic Acids;Romanicardic acid;(Z)-2-Hydroxy-6-(8-pentadecenyl)benzoic acid;Spectrum5_000899;Anacardic Acid 8'Z-Monoene;BSPBio_002625;Anacardic acid 8''Z-monoene
Cas No.
22910-60-7
分子式
C22H34O3
分子量
346.50
包装储存
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
生物活性

Ginkgolic Acid is a natural compound that inhibits SUMOylation with an IC50 of 3.0 μM in 体外研究 assay.

性状

Solid

IC50 & Target[1][2]

IC50: 3.0 μM (SUMOylation)

体外研究(In Vitro)

Ginkgolic acid inhibits the 体外研究 SUMOylation of RanGAP1-C2 with the IC50 values of 3.0 μM. The level of SUMOylated p53 is markedly reduced by the ginkgolic acid treatment. Importantly, ginkgolic acid does not affect protein ubiquitination in cells. Ginkgolic acid inhibits the binding between E1 and GA-BODIPY in a dose-dependent manner. Ginkgolic acid (31.2 μg/mL) inhibits HIV protease activity by 60%, compared with the negative control, and the effect is concentration-dependent. Ginkgolic acid treatment (50 and 100 μg/mL) effectively inhibits HIV infection in human PBMC cells. Ginkgolic acid at the concentrations up to 150 μg/mL does not cause any significant cytotoxicity in Jurkat cells. GA only inhibits the growth of tumorogenic cell lines in a both dose- and time-dependent manner. Tumor cells are treated with GA for 72 h, 70.53±4.54% Hep-2 and 63.5±7.2% Tca8113 cells are retarded at GO/G1 phase, and the percentage of apoptosis is 40.4±1.58 and 38.4±1.7%, respectively. GA-treated activated caspase-3 downregulates the expression of anti-apoptotic Bcl-2 protein and upregulates the expression of pro-apoptotic Bax protein, eventually leading to a decrease in the Bcl-2/Bax ratio in tumor cellsin human PBMC cells. Ginkgolic acid at the concentrations up to 150 μg/mL does not cause any significant cytotoxicity in Jurkat cells.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature or refrigerated transportation.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
结构分类
来源
参考文献
溶解度数据
体外研究: 

DMSO : 100 mg/mL (288.60 mM; Need ultrasonic)

配制储备溶液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.8860 mL 14.4300 mL 28.8600 mL
5 mM 0.5772 mL 2.8860 mL 5.7720 mL
10 mM 0.2886 mL 1.4430 mL 2.8860 mL
*

产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,建议在 6 个月内使用,-20°C 储存时,建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    建议依照次序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.75 mg/mL (7.94 mM); Clear solution

    此方案可获得 ≥ 2.75 mg/mL (7.94 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH?O 中,得到澄清透明的生理盐水溶液
  • 2.

    建议依照次序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.75 mg/mL (7.94 mM); Clear solution

    此方案可获得 ≥ 2.75 mg/mL (7.94 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

相关产品

更多
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2